KTE-X19 anti-CD19 CAR T-cell therapy in adult relapsed/refractory acute lymphoblastic leukemia: ZUMA-3 phase 1 results

Shah, BD; Bishop, MR; Oluwole, OO; Logan, AC; Baer, MR; Donnellan, WB; O'Dwyer, KM; Holmes, H; Arellano, ML; Ghobadi, A; Pagel, JM; Lin, Y; Cassaday, RD; Park, JH; Abedi, M; Castro, JE; DeAngelo, DJ; Malone, AK; Mawad, R; Schiller, GJ; Rossi, JM; Bot, A; Shen, T; Goyal, L; Jain, RK; Vezan, R; Wierda, WG

Shah, BD (corresponding author), H Lee Moffitt Canc Ctr & Res Inst, 12902 Magnolia Dr,FOB3-Heme, Tampa, FL 33612 USA.

BLOOD, 2021; 138 (1): 11

Abstract

ZUMA-3 is a phase 1/2 study evaluating KTE-X19, an autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, in adult relapsed/refractory (......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索